Trump’s Medicare Pricing Policy Could Mean Big Disruptions to Medical Benefits

Posted by Howard Deutsch on Tue, Nov 13, 2018

Gustavo Poblete co-authored this blog post with Howard Deutsch.

The Trump administration rolled out a significant policy proposal aimed at reducing the prices that Medicare pays for prescription drugs covered under the Part B medical benefit. While the policy is positioned as a “pilot” covering half the country, it will, if implemented as proposed, bring substantially greater disruption to drug pricing, contracting and distribution than purportedly envisioned by the government. Manufacturers with drugs covered under the medical benefit will need to fully reevaluate their strategies to adapt.


>
Read More

Who’s the Real Target of Trump’s Medicare Price Policy?

Posted by Howard Deutsch on Mon, Nov 05, 2018

Bill Coyle, Pratap Khedkar and Gustavo Poblete co-authored this post with Howard Deutsch.

When President Trump announced at the Department of Health and Human Services that the federal government would be taking “revolutionary” action on drug prices, he had harsh words for the “global freeloading” by foreign nations that demand low prices while saddling Americans with the high prices that fund pharmaceutical industry R&D. And he came with a plan: Medicare Part B prices will be lowered by indexing to drug prices in other wealthy nations.


>
Read More